American Cancer Society Recommends Biennial PSA Screening for Prostate Cancer

The American Cancer Society now formally recommends PSA blood screening for prostate cancer — every two years for average-risk men aged 50 to 69, and annually from 45 for those at higher risk — a shift announced on November 12 after sixteen years of “talk to your doctor” guidance, and one now fueling momentum for organized screening in Italy.

For sixteen years, the message from one of the world’s most authoritative scientific bodies was, in essence, “discuss it with your doctor and decide together.” As urologists writing in Il Sole 24 ORE put it this week, today the American Cancer Society states clearly that the benefits of PSA screening outweigh the risks, and recommends it outright.

The change rests on two pillars. The European Randomised Study of Screening for Prostate Cancer (ERSPC), after 23 years of follow-up, showed that screening reduces deaths from prostate cancer and that the benefit grows over time, while also cutting diagnoses made only after the disease has already spread — the hardest to cure, Il Sole 24 ORE reported.

And clinicians have learned to limit the harms that long held screening back: too many biopsies and too many treatments for tumors that would never have caused problems.

Dr. William Dahut, chief scientific officer of the American Cancer Society and a co-author of the guideline, framed the equity stakes: “With a direct recommendation in favor of screening and supporting earlier and more frequent checks for African American men, we also aim to reduce the disparities linked to prostate cancer and the burden of the disease,” according to Sanità Informazione.

PSA Test Measures Prostate Protein, Not Cancer Diagnosis

  • A PSA test is a simple blood draw measuring a protein made by the prostate. A high reading does not mean cancer — the first step now is simply repeating the test a few weeks later, because levels often return to normal on their own.
  • Screening is a recommendation, not an obligation. The guideline says patients should be told the benefits, limitations, and possible harms before deciding.
  • You don’t wait for symptoms. A tumor still confined to the prostate often causes none, and urinary troubles usually come from benign conditions — so waiting to feel unwell is not a reliable strategy, Mondosanità explained.

Exactly Who Should Test, and How Often

The guideline, published in CA: A Cancer Journal for Clinicians (DOI: 10.3322/caac.70112) by lead authors including Richard M. Hoffman of the University of Iowa Carver College of Medicine and Andrew M. D. Wolf of the University of Virginia School of Medicine, tailors intervals to risk.

The Wom Healthy summarized the thresholds: an elevated reading — 3.0 ng/mL or higher under age 70, or 6.5 ng/mL or higher after 70 — triggers a repeat test first, then a multiparametric MRI if the value persists, before any biopsy is even considered.

Prostata, svolta americana sul PSA: test ogni 24 mesi dai 50 anni in su
Photo: Mondosanità
Risk group Start age Interval (ages 45–69)
Average risk (no family history, not Black) 50 Every 2 years
Black men 45 Every year
Strong family history (multiple first-degree relatives, or one diagnosed before 65) 45 Every year
Single first-degree relative diagnosed at 65 or older 45 Every 2 years
Ages 70–74 — Decide case by case
Ages 75 and older, or life expectancy under 10 years — Not recommended

One notable novelty: the American guidelines state that digital rectal examination is not recommended as a screening test — a blood draw is enough. Il Sole 24 ORE noted this removes one of the barriers, including a psychological one, that keeps many men away from prevention.

Why the Two-Year Interval Beats Annual Testing

For average-risk men, the biennial schedule offers what The Wom Healthy called an excellent compromise: it keeps nearly intact the capacity to save lives compared with annual testing while drastically cutting false alarms and biopsies. That matters because avoiding unnecessary treatment has a concrete value — surgery and radiation therapy can leave consequences for urinary continence and sexual function, and, depending on the treatment, bowel problems, Mondosanità reported.

Prostate cancer screening advice has changed. — USA Medical

When a low-risk tumor is found, the first choice is no longer surgery but active surveillance: periodic checks, with treatment only if and when needed, Il Sole 24 ORE explained. Adam Feldman, who leads urologic oncology at the Mass General Brigham Cancer Institute in Boston, stressed the value of early detection and treatment in the initial phases, according to Mondosanità's reporting of US media.

From Atlanta to Rome: Will Italy Follow?

These are recommendations designed for the American reality, and not everything transfers to Italy as-is, Il Sole 24 ORE cautioned.

But the direction matches the one indicated by the European Union, which since 2022 has invited member states to evaluate organized prostate screening programs — and the same American experts remind health systems that these recommendations work only where programs are organized, capable of following the person from the first test through any follow-up.

The stakes are substantial at home. Prostate cancer is the most frequent cancer in men; in Italy roughly 485,000 men live with the diagnosis, and more than 40,000 new diagnoses were estimated for 2024, Quotidiano Sanità reported.

That outlet also covered a webinar organized for Tuesday by Europa Uomo Italia with the University of Naples Federico II, titled “PSA beyond the number: understanding to decide better,” aimed at helping citizens discuss the test with their doctor. “A report can generate doubts and fears: finding clear answers is part of the quality of care,” said Daniela Terracciano, dell’Università degli Studi di Napoli Federico II.

In the United States, the disease is the second-leading cause of cancer death among men; the American Cancer Society estimates 333,830 new diagnoses and 36,320 deaths for 2026, with incidence 67% higher and mortality nearly double among African American men compared with white men, Sanità Informazione reported.

Screening Not Recommended for Men 75 and Older

  • Men aged 75 and older, or anyone with a life expectancy under ten years, should not undergo screening, per the guideline, because real benefits are unlikely.
  • Between 70 and 74, the balance of benefits and harms remains uncertain and the decision should be individualized with a clinician.
  • An elevated PSA alone is not a diagnosis. Consult a doctor if a repeat test remains high; the appropriate next step is MRI-based assessment, not automatic biopsy.
  • Men should be informed before screening that follow-up of an elevated PSA may involve further tests, and that low-risk cancers will initially be managed with active surveillance.

Where the Evidence Comes From — and Who Paid

Transparency on method and funding matters here. The American Cancer Society conducted a systematic review of the scientific evidence and commissioned a modeling study to evaluate the benefits and risks of different screening strategies before concluding that the benefits outweigh the harms, Sanità Informazione reported, according to Il Sole 24 ORE.

The guideline appears in the Society's own peer-reviewed journal, CA: A Cancer Journal for Clinicians, whose 2026 update the Wom Healthy outlet cited with the DOI linked above.

One flag worth reading carefully: the Italian webinar on PSA was held with the “non-conditioning contribution” of Beckman Coulter Diagnostics, a laboratory diagnostics manufacturer — a disclosure Quotidiano Sanità printed plainly, and readers should weigh it when considering industry-sponsored education on testing.

American Cancer Society Recommends Biennial PSA Screening for Prostate Cancer
Photo: Quotidiano Sanità

The next figure to watch is whether Italy’s institutions translate the EU’s 2022 invitation into an organized program of their own — the step that, as the urologists wrote in Il Sole 24 ORE, these recommendations require to work at all.

References

  • Hoffman RM, Wolf AMD, Etzioni RD, et al. American Cancer Society guideline for the early detection of prostate cancer, 2026. CA: A Cancer Journal for Clinicians. https://doi.org/10.3322/caac.70112
  • Il Sole 24 ORE — “Tumore della prostata: lo screening raccomandato negli Usa, ora si muova anche l’Italia.”
  • Mondosanità — “Prostata, svolta americana sul PSA: test ogni 24 mesi dai 50 anni in su.”
  • Quotidiano Sanità — “PSA e tumore alla prostata: un webinar per capire meglio e decidere.”
  • Sanità Informazione — “Tumore della prostata, l’American Cancer Society aggiorna le linee guida.”
  • Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA/SUO guideline, Part I. J Urol. 2023;210(1):45–53.

Readers should discuss screening decisions with their own physician.

Photo of author

Health Desk

Health Desk at Archyde.

Vincent Van Gogh’s Châtaigniers En Fleurs Shattered the Art World Ceiling